Caxton Associates (New York)’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.6M | Sell |
60,414
-16,211
| -21% | -$430K | 0.05% | 130 |
|
|
2024
Q3 | $2.22M | Buy |
76,625
+50,232
| +190% | +$1.45M | 0.08% | 104 |
|
|
2024
Q2 | $738K | Buy |
+26,393
| New | +$738K | 0.03% | 279 |
|
|
2023
Q4 | – | Sell |
-45,018
| Closed | -$1.49M | – | 521 |
|
|
2023
Q3 | $1.49M | Buy |
45,018
+3,043
| +7% | +$101K | 0.21% | 84 |
|
|
2023
Q2 | $1.54M | Buy |
+41,975
| New | +$1.54M | 0.23% | 96 |
|
|
2023
Q1 | – | Sell |
-2,874,544
| Closed | -$147M | – | 591 |
|
|
2022
Q4 | $147M | Buy |
2,874,544
+8,794
| +0.3% | +$451K | 9.83% | 3 |
|
|
2022
Q3 | $125M | Sell |
2,865,750
-21,580
| -0.7% | -$944K | 16.71% | 1 |
|
|
2022
Q2 | $151M | Sell |
2,887,330
-1,932
| -0.1% | -$101K | 14.71% | 1 |
|
|
2022
Q1 | $150M | Buy |
2,889,262
+498,845
| +21% | +$25.8M | 12.17% | 3 |
|
|
2021
Q4 | $141M | Buy |
2,390,417
+910,417
| +62% | +$53.8M | 14.37% | 1 |
|
|
2021
Q3 | $63.7M | Buy |
+1,480,000
| New | +$63.7M | 7.03% | 3 |
|
|
2019
Q4 | – | Sell |
-13,885
| Closed | -$473K | – | 507 |
|
|
2019
Q3 | $473K | Buy |
+13,885
| New | +$473K | 0.09% | 136 |
|
|
2018
Q3 | – | Sell |
-10,654
| Closed | -$367K | – | 467 |
|
|
2018
Q2 | $367K | Buy |
+10,654
| New | +$367K | 0.02% | 246 |
|
|
2014
Q2 | – | Sell |
-105,400
| Closed | -$3.21M | – | 213 |
|
|
2014
Q1 | $3.21M | Buy |
+105,400
| New | +$3.21M | 0.2% | 67 |
|